Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy

Edoardo G. Giannini, Nezam H. Afdhal, Samuel H. Sigal, Andrew J. Muir, K. Rajender Reddy, Shanthi Vijayaraghavan, Magdy Elkashab, Manuel Romero-Gómez, Geoffrey M. Dusheiko, Malini Iyengar, Sandra Y. Vasey, Fiona M. Campbell, Dickens Theodore

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Aim: Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus (HCV) infection and cirrhosis, although it can also be observed in patients without cirrhosis by a virus-mediated phenomenon. This study assessed the prevalence, characteristics, and outcomes of antiviral therapy in patients with chronic HCV infection and thrombocytopenia not associated with cirrhosis. Methods: The study included 1268 patients with HCV infection and thrombocytopenia enrolled in the phase 3 ENABLE studies that assessed the impact of eltrombopag on achieving a sustained virologic response to pegylated interferon and ribavirin. The study population was subdivided according to baseline FibroSURE test results into patients with non-cirrhosis (FibroSURE

Original languageEnglish
Pages (from-to)1301-1308
Number of pages8
JournalJournal of Gastroenterology and Hepatology
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Keywords

  • Cirrhosis
  • Eltrombopag
  • Hepatitis C virus
  • Interferon
  • Platelets

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy'. Together they form a unique fingerprint.

Cite this